Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brazikumab · 1 trial · 1 indication
Cmax of brazikumab in healthy Chinese and White participants will be evaluated.
AUCinf of brazikumab in healthy Chinese and White participants will be evaluated.
AUClast of brazikumab in healthy Chinese and White participants will be evaluated.
AUC0-28d of brazikumab in healthy Chinese and White participants will be evaluated.
| Arm | Type | Description |
|---|---|---|
| Group 1 [Healthy Chinese Participants] | EXPERIMENTAL | Participants will receive a single intravenous (IV) infusion of brazikumab dose 1 on Day 1. |
| Group 2 [Healthy Chinese Participants] | EXPERIMENTAL | Participants will receive a single IV infusion of brazikumab dose 2 on Day 1. |
| Group 3 [Healthy Chinese Participants] | EXPERIMENTAL | Participants will receive a single subcutaneous (SC) injection of brazikumab dose 3 on Day 1. |
| Group 4 [Healthy Chinese Participants] | EXPERIMENTAL | Participants will receive a single SC injection of brazikumab dose 4 on Day 1. |
| Group 5 [healthy White participants] | EXPERIMENTAL | Participants will receive a single IV infusion of brazikumab dose 2 on Day 1. |
| Group 6 [healthy White participants] | EXPERIMENTAL | Participants will receive a single SC injection of brazikumab dose 4 on Day 1. |
| Name | Type | Description |
|---|---|---|
| Brazikumab | DRUG | Participants will receive IV or SC injection of brazikumab as per the group they are assigned. |
Inclusion Criteria: * Participant is capable of giving signed and dated informed consent * Healthy Chinese and White male and female participants aged 18 to 55 years (inclusive), at the time of signing the informed consent * For White participants only: * Participant must be of European descent ...
Brazikumab is an investigational monoclonal antibody developed by AstraZeneca PLC. It is designed to inhibit the IL12B and IL23A targets. The drug has been studied in a Phase 1 clinical trial involving healthy participants, but its specific therapeutic indications have not been disclosed.
Brazikumab targets IL12B and IL23A. It is an inhibitor of these molecules, which are involved in immune signaling pathways. By inhibiting IL12B and IL23A, brazikumab may modulate immune responses, though its exact clinical applications are still under investigation.
Brazikumab is being developed by AstraZeneca PLC, a pharmaceutical company traded on the Nasdaq under the ticker symbol AZN. AstraZeneca is responsible for the research and clinical development of this monoclonal antibody.
Brazikumab is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. As an investigational drug, it has not been approved by the FDA for any indication.
Brazikumab has been evaluated in a completed Phase 1 trial, NCT05033431, titled "Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants." This trial enrolled 48 healthy volunteers in the United States.